Full-Time

Group Leader

Analytical Development

Posted on 3/22/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Compensation Overview

$150k - $174k/yr

+ Equity Component + Comprehensive Benefits

Senior, Expert

San Carlos, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Vaxcyte referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 8+ years relevant industry experience; MS or BS with 15+ years of industry experience in Pharma/ Biotech industry required.
  • Proven leadership skills.
  • Outstanding organization and planning skills.
  • Must be a strong scientific leader who can guide scientists with clear goals of developing analytical methods, and critically and skillfully review and assess analytical methods under development. May need to provide direction for troubleshooting various issues during method development.
  • Proven track record of analytical development leadership for biologics and small molecules, experience with vaccines, carbohydrate, or conjugates is a plus.
  • Extensive expertise in U/HPLC, CE, SDS-PAGE, mass spectrometry, and other analytical technologies as applied to protein analytical method development, trouble shooting and validation for GMP release and stability testing.
  • Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.
  • Experience in protein, carbohydrate, and conjugates analysis is highly desired, for example hands on experience and theoretical understanding of HPAEC-PAD, HPLC/UV/FLD, SEC-LC, SEC-MALS, and colorimetric assays are highly desired.
  • Attention to detail and excellent skills in record keeping / documentation. Critical thinking and ability to analyze data.
  • Strong interpersonal skills: ability to communicate effectively both verbally and in written formats.
  • Ability to work with minimum supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.
Responsibilities
  • Manage R&D ADQC stability programs, such as but not limited to, providing sampling volume forecast, coordinating with stability group on stability set-down and monitoring each stability pull-point.
  • Manage in-house routine testing, such as stability and release testing, characterization, in-process samples analysis and reference standard qualification. Responsible for the overall quality and compliance of all the testing.
  • Provide technical direction, mentorship and coaching to the analytical development team.
  • Lead the design and interpretation of experiments to analyze raw materials.
  • Keep accurate and detailed records of experiments in laboratory notebooks.
  • Summarize data and communicate to cross functional team such as stability, PD and PM.
  • Represent ADQC to attend X-Functional lab operation alignment meeting led by facility.
  • Work within a team environment and provide support to further team objectives.
Desired Qualifications
  • Experience with vaccines, carbohydrate, or conjugates is a plus.
  • Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively bypass the complex defenses of bacteria while still provoking an immune response. This method sets Vaxcyte apart from competitors who rely on traditional cell-based vaccine production. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • VAX-24 has FDA Breakthrough Therapy designation, expediting its approval process.
  • The global pneumococcal vaccines market is projected to grow at a 5.6% CAGR until 2030.
  • Vaxcyte's recent $1.5 billion public offering strengthens its financial position for growth.

What critics are saying

  • Competition from Pfizer's Prevnar 20 could impact Vaxcyte's market share.
  • Emerging bacterial strains may require additional R&D, delaying product timelines.
  • Reliance on XpressCF™ platform poses risks if licensing disputes or failures occur.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte's vaccines aim to overcome limitations of traditional cell-based methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 3%

2 year growth

↑ 1%
Business Insider
May 1st, 2025
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.

Clinical Trial Vanguard
Mar 31st, 2025
Vaxcyte Announces Positive VAX-24 Infant Phase 2 Results

Vaxcyte aims to develop superior vaccines against bacterial diseases, utilizing advanced synthetic techniques like their XpressCF(TM) cell-free protein synthesis platform.

MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

INACTIVE